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Background: Transfer of healthy tissue is commonly used in the treatment of complicated
wounds and in reconstruction of tissue defects. Recently, microvascular lymph node
transfer (LN) has been used to improve the lymphatic function in lymphedema patients. To
elucidate the biological effects of flap transfer (with and without lymph nodes), we have
studied the postoperative production of proinflammatory, anti-inflammatory, prolym-
phangiogenic and antilymphangiogenic cytokines, and growth factors (interleukin 1a
[IL-1a], IL-1b, tumor necrosis factor a [TNF-a], IL-10, transforming growth factor b1 [TGF-b1],
IL-4 and IL-13, and vascular endothelial growth factor C [VEGF-C] and VEGF-D) in post-
operative wound exudate samples.
Methods: Axillary wound exudate samples were analyzed from four patient groups: axillary
lymph node dissection (ALND), microvascular breast reconstruction (BR), LN, and com-
bined LN and BR (LN-BR).
Results: The concentration of proinflammatory cytokines was low in all the flap transfer
groups as opposed to the ALND group, which showed an extensive proinflammatory
response. The level of anti-inflammatory and antifibrotic cytokine IL-10 was increased in
the LN-BR group samples compared with the ALND and BR groups. In the LN and LN-BR
groups, the cytokine profile showed an anti-inflammatory response.
Conclusions: Transfer of healthy tissue hinders the proinflammatory response after surgery,
which may explain the beneficial effects of flap transfer in various patient groups. In
addition, flap transfer with lymph nodes seems to also promote an antifibrotic effect. The
clinical effects of LN in lymphedema patients may be mediated by the increased produc-
tion of prolymphangiogenic growth factor (VEGF-C) and antifibrotic cytokine (IL-10).
ª 2015 Elsevier Inc. All rights reserved.1. Introduction response, followed by proliferative and remodeling phases.Surgery and trauma lead to tissue injury and wound healing,
which in the early stages is dominated by a proinflammatoryic and General Surgery, T
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lymphedema. Transfer of healthy tissue is commonly used in
the treatment of complicated and chronic wounds [1,2]. Few
studies have evaluated the inflammatory effects of flap
transfer surgery used in breast reconstruction (BR). Micro-
vascular BR has been shown to result in a greater systemic
elevation of the acute phase inflammatory C reactive protein
[3] and interleukin 6 (IL-6) [4] compared with local pedicular
latissimus dorsi or lateral thoracodorsal BR flaps. However,
both of these studies evaluated only the systemic response of
surgery, and comparison to nonflap surgery was not per-
formed. Thus far, little is known about the effects of flap
transfer on the local wound healing environment.
More recently, autologous microvascular lymph node
transfer (LN) has been used to improve the lymphatic drainage
in lymphedema patients [5e7]. In addition to restoring the
lymphatic flow, LN offers a possibility to retain the lymphatic,
immunologic, and sentinel node functions of the affected
limb. Interestingly, also flap transfer without lymph nodes
(normal BR) has been shown to reduce the lymphedema
symptoms of the arm in some postsurgical lymphedema pa-
tients [8e10]. This suggests that in some cases flap transfer
alone modifies the local wound environment favorable to
lymphangiogenesis.
Human lymph nodes express lymphatic vascular endo-
thelial growth factor C (VEGF-C) [6], which is secreted into
axillary wound exudate after microvascular LN [7]. Results
from the preclinical lymphedema models using VEGF-C or
VEGF-D have demonstrated the ability of these factors to
induce the growth of new lymphatic vessels [11e13], thus
providing a biological basis for the microsurgical LN method.Fig. 1 e Patient groups for wound exudate samples are as follow
analyzed from wound exudate samples are as follows: proinfla
inflammatory cytokines (IL-10 and TGF-b1), profibrotic cytokines
(Color version of figure is available online.)Recent studies have shown that in addition to VEGF-C, lym-
phangiogenesis is regulated by a coordinated expression of
proinflammatory and anti-inflammatory cytokines [14e16].
Furthermore, fibrosis and scarring are known to be key in-
hibitors of lymphatic regeneration [17]. Therefore, the factors
affecting chronic inflammation and fibrosis are also a major
topic of interest.
The clinical benefits of flap transfer surgery in various
wound healing disorders are acknowledged [1,2], although
there is lack of supportive biological evidence. To provide
more information about the local biological and immunologic
effects of flap transfer with and without lymph nodes, we
decided to evaluate the postoperative production of proin-
flammatory cytokines (IL-1a, IL-1b, and tumor necrosis factor
alpha [TNF-a]), anti-inflammatory cytokines (IL-10 and
transforming growth factor beta1 [TGF-b1]), profibrotic cyto-
kines (IL-4 and IL-13), and lymphatic growth factors (VEGF-C
and -D) involved in wound healing and lymphangiogenesis in
different patient groups: axillary lymph node dissection
(ALND), microvascular BR, LN, and combined LN and BR (LN-
BR; study design in Fig. 1).2. Patients and methods
2.1. Patient samples for cytokine analysis
Permission for collecting patient sampleswas approved by the
Ethical Committee of the Turku University Hospital. All pa-
tients signed an approval for sample collection and approved
the use of their patient information in the study. Postoperatives: ALND, LN, BR, and LN-BR. Cytokines and growth factors
mmatory cytokines (IL-1a, IL-1b, and TNF-a), anti-
(IL-4, IL-13), and lymphatic growth factors (VEGF-C and -D).
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and sixth postoperative day (POD) from LN (n ¼ 8), LN-BR
(n ¼ 8) and, for controls, BR (n ¼ 8) and ALND (n ¼ 8) pa-
tients. In addition, wound exudate samples were collected
from flap donor sites (n ¼ 9) on the first and sixth POD.
Microvascular LN was performed to lymphedema patients as
previously described [6,7]. The BR group consisted of post-
mastectomy patients without lymphedema symptoms. Prep-
aration of the axilla was similar in all the flap groups (LN,
LN-BR, and BR) as the thoracodorsal vessels were used as
recipient vessels in all the BR flaps and the retrograde thor-
acodorsal vessels in the lymphatic flaps. ALND patients
underwent a routine breast cancer operation (mastectomy or
breast resection) with removal of axillary lymph nodes due to
metastases. The decision for ALND was made preoperatively
based on imaging and biopsy results, and thus sentinel node
biopsy was not performed. Exclusion criteria in the ALND
group were preoperative oncological treatments or previous
axillary surgery.
2.2. Evaluation of wound exudate cytokines
A protease inhibitor (cOmplete EDTA-free Protease Inhibitor
Cocktail Tablets; Roche Diagnostics, Mannheim, Germany)
was added to the wound exudate samples, followed by
centrifugation to separate the supernatant and cell pellet [7].
Supernatant cytokine protein concentrations were measured
using enzyme-linked immunosorbent assays (R&D Systems,
Minneapolis, MN) according to the manufacturer’s in-
structions. Optical densities were read with a microplate
reader (Infinite 200; TecanGroup Ltd, Ma¨nnedorf, Switzerland)
and converted to picograms per milliliter with MasterPlex
ReaderFit 2.0.0.77 (MiraiBio Group of Hitachi Solutions Amer-
ica, Ltd, San Francisco, CA).
2.3. Statistical analyses
All tests were performed two tailed and P-values <0.05
considered statistically significant. Differences between the
treatment groups were tested separately on the first and
sixth POD, using either parametric (analysis of variance) or
nonparametric (KruskaleWallis) one-way analysis of variance,
andwhen appropriate, followed by pairwise comparisons tests.Fig. 2 e Proinflammatory cytokine IL-1b. **P< 0.01.For normally distributed data, effect sizes for pairwise com-
parisons are reported as Hedges’ g statistic with a 95% confi-
dence interval (CI), whereas Cliff’s delta statistic with a 95% CI
is used for nonnormally distributed data. Results are expressed
as arithmetic means (standard deviation) for normally
distributed data (Figs. 3,5,7A and B and Supplementary Figs.
4,6B,7,8) and geometric means (95% CIs) for log-transformed
data (Figs. 2,4,6 and Supplementary Figs. 1A and B,2,3A and
B,5,6A), with error bars in the respective figures representing
95%CIs. For nonnormally distributed and nontransformeddata
(Fig. 5 and Supplementary Fig. 7), results are reported as me-
dians (interquartile ranges), with horizontal lines in the graphs
indicating medians, boxes interquartile ranges, and whiskers
extending from minimum to maximum values. A detailed
description of the statistical analyses can be found in the
supplementary data files.3. Results
3.1. Proinflammatory cytokines IL-1a, IL-1b, and TNF-a
Analysis of the cytokine concentrations revealed only
nonsignificant and nonsubstantial differences in the IL-1a
levels between any of the groups on the first or sixth POD
(Supplementary Fig. 1A and B, Supplementary Table 1).
As for the IL-1b concentrations on the first POD (Fig. 2,
Supplementary Table 2), the levels were significantly higher in
the ALND group (P ¼ 0.001) and nonsignificantly but still
substantially higher also in the LN-BR group (P ¼ 0.066,
g ¼ 1.38, 95% CI ¼ 0.29e2.47), when compared to the BR group.
For the rest of the pairwise comparisons, the differences were
nonsignificant and nonsubstantial. On the sixth POD
(Supplementary Fig. 2, Supplementary Table 2), the IL-1b
concentrations no longer differed significantly or substan-
tially between the groups.
In terms of TNF-a, only nonsignificant and nonsubstantial
differences between the groups were observed on the first
POD (Supplementary Fig. 3A, Supplementary Table 3). How-
ever, on the sixth POD (Supplementary Fig. 3B, Supplementary
Table 3), even though the groupwise differences were
nonsignificant, the level of TNF-a in the ALND group was still
substantially higher than that of the LN-BR group (P ¼ 0.052,Fig. 3 e Immunoregulatory cytokine IL-10. **P< 0.01.
Fig. 4 e Transforming growth factor b1. **P< 0.01.
Fig. 6 e Vascular endothelial growth factor C. ***P< 0.001.
Preliminary VEGF-C results with smaller number of
samples have been published in our earlier report [7].
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were found.
3.2. Anti-inflammatory cytokines IL-10 and TGF-b1
In terms of IL-10, the groupwise differences in the concen-
trations turned out nonsignificant and nonsubstantial on the
first POD (Supplementary Fig. 4, Supplementary Table 4). On
the sixth POD, the IL-10 concentrations were higher in the LN
groups, LN and LN-BR, when compared to the control groups,
ALND and BR (Fig. 3, Supplementary Table 4). Although this
difference was significant only between LN-BR and ALND
(P ¼ 0.004), the comparison between LN-BR and BR proved still
substantial (P ¼ 0.165, g ¼ 1.36, 95% CI ¼ 0.28e2.45). As for the
rest of the groupwise comparisons, the results were nonsig-
nificant and nonsubstantial.
To determine whether the differences between the LN (LN
and LN-BR) and the BR control groups were due to the trans-
ferred lymph nodes or possibly other characteristics of the
patient groups (e.g., lymphedema versus nonlymphedema),
the IL-10 concentrations were measured also from flap donor
site wound exudate. However, no significant or substantial
differences were found between the flap transfer groups
either on the first or sixth POD (data not shown).
As for TGF-b1, the protein levels on the first POD (Fig. 4,
Supplementary Table 5) were significantly higher in all otherFig. 5 e Profibrotic cytokine IL-13. *P< 0.05.groups when comparedwith ALND: ALND versus BR, P¼ 0.003;
ALND versus LN, P ¼ 0.010; and ALND versus LN-BR, P ¼ 0.001.
Among these flap transfer groups, the TGF-b1 concentrations
were similar and the differences were nonsignificant and
nonsubstantial. In contrast to the first POD, the levels on the
sixth POD were low also in the flap transfer groups and no
significant or substantial differences were observed
(Supplementary Fig. 5, Supplementary Table 5).3.3. Profibrotic cytokines IL-4 and IL-13
Analysis of the exudate samples revealed no significant or
substantial differences in the IL-4 levels between any of the
groups on the first or sixth POD (Supplementary Fig. 6A and B,
Supplementary Table 6).
On the other hand, more prominent groupwise differences
were observed in the IL-13 concentration on the first POD
(Fig. 5, Supplementary Table 7). However, only comparisons of
BR with ALND and LN were significant, even though the level
of IL-13 was virtually zero in the ALND and LN groups and
markedly higher in the BR and LN-BR groups: BR versus ALND,
P ¼ 0.029; BR versus LN, P ¼ 0.029. The rest of the groupwise
differences were nonsignificant and nonsubstantial. On the
sixth POD, no significant or substantial differences were
observed (Supplementary Fig. 7, Supplementary Table 7).A B
Fig. 7 e Vascular endothelial growth factor D. *P< 0.05;
**P< 0.01; ***P< 0.001.
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VEGF-D
Similar to our previous study with a smaller number of pa-
tients [7], significant groupwise differences in the VEGF-C
concentration were observed on the first POD (Fig. 6,
Supplementary Table 8). Compared with ALND, the level of
VEGF-C was significantly higher in the BR (P < 0.001) and LN-
BR (P < 0.001) groups, and in addition, nonsignificantly but
still substantially higher also in the LN group (P ¼ 0.099,
g ¼ 1.51, 95% CI ¼ 0.42e2.61). The differences between these
three groups were nonsignificant and nonsubstantial. On the
sixth POD, the VEGF-C concentrations in the flap groups were
similar to ALND and no significant or substantial differences
were found (Supplementary Fig. 8, Supplementary Table 8).
Interestingly, the results from the VEGF-D level analysis
were somewhat reciprocal. On the first POD, the level of VEGF-
D was highest in the ALND group, significantly higher when
comparedwith the LN groups: ALND versus LN, P¼ 0.017; ALND
versus LN-BR, P¼ 0.047 (Fig. 7A, Supplementary Table 9). On the
sixth POD, the situation was further emphasized (Fig. 7B,
Supplementary Table 9) and all comparisons with the ALND
group were now significant: ALND versus BR, P ¼ 0.004; ALND
versusLN,P¼0.001;andALNDversusLN-BR,P<0.001.As for the
rest of the groupwise comparisons of both PODs, only nonsig-
nificant and nonsubstantial differences were observed.
3.5. Wound exudate cytokine profiles
To summarize the results, groupwise cytokine profiles were
generated from the relative concentrations (groupwise mean
divided by the grandmean; Fig. 8A and B). On the first POD, the
level of proinflammatory cytokines was notably high for the
ALND group and low for the BR group. The level of profibrotic
cytokines was, in contrast, low for the ALND group and
high for the BR group, particularly with IL-13. As for the
anti-inflammatory cytokine concentrations, the differences
between the ALND and BR groups were less prominent. The
results on the sixth POD were similar to those of the first POD,
with the exception of TNF-a, now somewhat elevated also in
the BR group. Interestingly, in the LN groups, cytokine profiles
were less distinct on both PODs, as the relative concentrations
were mainly quite similar to the grand mean, the mostA
Fig. 8 e Summary of the relative cytokine concentrations in the d
according to their type: proinflammatory cytokines are located o
inflammatory cytokines on the right side of the figure. (Color vepersistent exceptions being the low TNF-a and IL-13 levels of
the LN group on both the first and sixth POD, and the elevated
IL-10 levels on the sixth POD in the LN-BR and, to a smaller
degree also in the LN group.4. Discussion
In this study, we investigated postoperative axillary exudate
samples from four patient groups (ALND, BR, LN, and LN-BR;
Fig. 1). Our results showed that the concentration of anti-
inflammatory cytokines was increased after flap transfer,
whereas in the ALND patients the proinflammatory cytokines
dominated the profile. In addition, flap transfer with lymph
nodes seemed to promote also an antifibrotic response (Figs. 8
and 9). Furthermore, we observed unexpected differences in
the VEGF-C and VEGF-D production profiles (summary in
Fig. 9). This is to our knowledge the first study investigating
the inflammatory effects of LN surgery and one of the few
studies elucidating the local biological mechanisms of flap
transfer.
4.1. Transfer of healthy tissue may reduce the local
proinflammatory response
Inflammation seems to play a diversified role in wound
healing and the development of lymphedema. Several studies
have demonstrated that inflammation is closely related to
lymphangiogenesis, and proinflammatory cytokines induce
lymphangiogenic growth factor (VEGF-C) expression in experi-
mental settings [14,15]. On the contrary, lymphatic stasis is
known to initiate chronic inflammation and tissue fibrosis
resulting in worsening of the lymphatic function [18]. Further-
more, lymphedema has been associated with a similar gene
expression profile as inflammation in a mouse model [19]. Ac-
cordingtoourresults, it seemsthatremovalofaxillary lymphatic
tissue promotes a proinflammatory response, whereas transfer
of healthy tissue to the axillary area may reduce this effect.
There seemed to be no significant differences in the
concentrations of proinflammatory cytokines between the
different flap transfer groups. We suggest that low production
of these proinflammatory cytokines is related primarily to the
transfer of healthy tissue, rather than the transferred lymphB
ifferent patient groups. Cytokines are arranged in the figure
n the left, profibrotic cytokines are in the middle, and anti-
rsion of figure is available online.)
Fig. 9 e Summary of the lymphatic and inflammatory
responses in the different patient groups. (Color version of
figure is available online.)
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transfer of a muscle flap decreases the production of proin-
flammatory cytokine TNF-a in an experimental fracture
model. The transfer of healthy tissue is commonly used in the
treatment of infectious wound complications [1,2] and con-
ditions caused by chronic skin inflammation [21]. In addition,
according to recent reports, normal BR (without lymph nodes)
may improve the lymphatic function of the affected arm in
some patients [8,9]. Furthermore, immediate BR seems to
reduce the risk of developing lymphedema [10]. It is therefore
possible that this clinical finding is partly related to the
smaller production of proinflammatory cytokines after flap
transfer. However, the production of lymphangiogenic growth
factor (VEGF-C) after flap transfer (also without lymph nodes)
[7] probably also plays a role in inducing beneficial effects in
lymphedema patients (Fig. 9).
4.2. Role of prolymphangiogenic growth factors VEGF-C
and VEGF-D
Members of the VEGFs family are important regulators of
angiogenesis and lymphangiogenesis [22,23]. VEGF-C and
VEGF-D both induce lymphangiogenesis by enhancing prolif-
eration, migration, and survival of lymphatic endothelial cells
[24]. Human lymph nodes express endogenous VEGF-C, which
provides a biological basis for themicrosurgical LNmethod [6].
In our earlier publication, we found an increased concentra-
tion of VEGF-C in the axillary wound exudate after flap
transfer in the LN and LN-BR groups and, surprisingly, also in
the BR group, compared with the ALND group [7]. This finding
was confirmed with a greater number of patient samples in
the present study. One explanation for the high VEGF-C con-
centration in the BR patients might be the finding that pa-
tients, who have not developed lymphedema after axillaryclearance, have actually residual axillary lymph nodes [25],
which are producing VEGF-C. In addition, recruited macro-
phages have been shown to be the source of VEGF-C after flap
transfer [26].
Interestingly, production of another important prolym-
phangiogenic growth factor, VEGF-D, differed markedly
from VEGF-C production after the LN. Even though VEGF-C
and -D activate same target receptors in the lymphatic
vessel endothelium, they have been reported to have
different roles also during the embryonic development and
growth [27,28]. High VEGF-D concentrations after the axil-
lary dissection may suggest that VEGF-D, rather than VEGF-
C, could play a role in the spontaneous lymphatic vascular
regrowth in the axilla after the breast cancer surgery.
Furthermore, the ALND patients in this study have under-
gone axillary dissection because of a breast cancer lymph
node metastasis, whereas the patients in the other groups
did not have active cancer at the time of surgery. Recently
operated carcinoma may alter the local VEGF-D concentra-
tion, as some breast cancer types are known to secrete
lymphatic growth factors to enhance lymphatic invasion
and lymph node metastasis [29e31].
4.3. LN promotes an anti-inflammatory and antifibrotic
response
Themost interesting finding in our study was the fact that the
concentration of IL-10 was higher in the LN groups when
compared with the BR and ALND groups. IL-10 is an anti-
inflammatory cytokine produced primarily by regulatory
macrophages [32]. The major physiological importance of IL-
10 is the prevention of uncontrolled harmful immunologic
reactions [32]. To our knowledge, the direct effect of IL-10 on
lymphangiogenesis has not been studied. However, it has
been shown that IL-10 can reduce scar formation and fibrosis
by inhibiting excessive deposition of extracellular matrix and
by regulating the arrangement of collagen fibers in regener-
ated tissue [33]. It has also been shown that IL-10 down-
regulates fibrosis promoting proinflammatory cytokines [34].
In both preclinical and clinical studies, IL-10 has been found to
be efficient in scar reduction and scar-improving therapies
[33,35,36]. In light of these previous studies, it is possible that
the clinical effects of LN are partly mediated by the increased
production of IL-10, which has anti-inflammatory and also
antifibrotic properties. The fact that the LN and LN-BR group
patients have lymphedema, whereas the BR and ALND pa-
tients do not have, should not affect the results, as we know
that immune cells have the ability to react to changing cir-
cumstances rather quickly. Therefore on POD 1 and 6, we are
most likely to see the effects of radical surgery rather than the
prior lymphedema.
TGF-b1 is an anti-inflammatory cytokine [37], and also a
regulator of tissue fibrosis and scarring in the later stages of
wound healing [38,39]. It has been demonstrated that inhibi-
tion of TGF-b1 leads to increased lymphatic repair during
wound healing [38]. IL-10 is also known to protect from TGF-
b1einduced fibrosis [33]. In our material, the TGF-b1 concen-
tration in the axillary wound exudate on the first POD was
higher in all the flap transfer groups compared with the ALND
group, but on the sixth POD the concentration was low in all
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studies, it can be speculated that in the early stages of wound
healing, the anti-inflammatory properties of TGF-b1 are
beneficial, but in the later stages of wound remodeling a high
concentration of TGF-b1 may inhibit lymphangiogenesis by
causing extensive fibrosis.
In addition to TGF-b1, also IL-4 and IL-13 have been
shown to be profibrotic and contribute to the development
of lymphedema [40]. The highest concentrations of these
profibrotic cytokines were found in the BR group, although
the concentrations were generally quite low. Thus, further
evidence is needed to clarify the role of these profibrotic
factors in the regulation of lymphangiogenesis in human
patients.5. Conclusions
The transfer of healthy tissue is commonly used in the
treatment of complicated wounds in various patient groups
[1,2,21]. Recently, flap transfer with lymph nodes has been
used in the treatment of lymphedema patients [5,6,41,42]. In
clinical studies, the LN seems to improve lymphatic flow of
the affected arm [5e7]. In addition, the role of flap transfer
without lymph nodes in the prevention and resolution of
lymphedema has been speculated recently [8e10]. In this
study, we have provided new information about the local
immunologic effects of flap transfer. According to our study,
flap transfer seems to prevent the proinflammatory response
after surgery, providing one explanation for the beneficial
effects seen after flap transfer in chronic inflammatory and
infectious wounds. Interestingly, LN seems to promote
not only a prolymphangiogenic effect, but also an anti-
inflammatory and antifibrotic response (Fig. 9). The cyto-
kine profile after an LN seems to differ from flap transfer
without lymph nodes, suggesting that also the transferred
lymph nodes are influencing locally on the wound healing
environment.
Acknowledgment
The authors acknowledge Dr Erkki Suominen, the crucial
member and teacher of surgical team. The authors
also thank all the nurses and secretaries in the Department
of Plastic and General Surgery of Turku University
Hospital.
This studywas supported by Special Governmental Funding
(EVO) allocated to Turku University Hospital and Finnish Cul-
tural Foundation Varsinais Suomi Regional Fund, TYKS Foun-
dation, Emil Aaltonen Foundation, and IdaMontini Foundation.
Authors’ contributions: T.P.V., member of surgical team,
wrote the article and collectedwound exudate samples. M.T.V
contributed to the collection and analysis of wound exudate
samples, statistics, and writing. E.S. contributed to the
collection of wound exudate samples and writing. A.M.S.,
member of surgical team, did the design of the study and
writing of the article. P.H. did the design of the study and
writing of the article.Disclosure
None.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jss.2015.04.041.r e f e r e n c e s
[1] Corten K, Struelens B, Evans B, Graham E, Bourne RB,
Macdonald SJ. Gastrocnemius flap reconstruction of soft-
tissue defects following infected total knee replacement.
Bone Joint J 2013;95-B:1217.
[2] Cabbabe EB, Cabbabe SW. Immediate versus delayed one-
stage sternal debridement and pectoralis muscle flap
reconstruction of deep sternal wound infections. Plast
Reconstr Surg 2009;123:1490.
[3] Blomqvist L, Malm M, Berg A, Svelander L, Kleinau S. The
inflammatory reaction in elective flap surgery. Plast Reconstr
Surg 1998;101:1524.
[4] Schmidt A, Bengtsson A, Tylman M, Blomqvist L. Pro-
inflammatory cytokines in elective flap surgery. J Surg Res
2007;137:117.
[5] Becker C, Assouad J, Riquet M, Hidden G. Postmastectomy
lymphedema: long-term results following microsurgical
lymph node transplantation. Ann Surg 2006;243:313.
[6] Saaristo AM, Niemi TS, Viitanen TP, Tervala TV, Hartiala P,
Suominen EA. Microvascular breast reconstruction and
lymph node transfer for postmastectomy lymphedema
patients. Ann Surg 2012;255:468.
[7] Viitanen TP, Visuri MT, Hartiala P, et al. Lymphatic vessel
function and lymphatic growth factor secretion after
microvascular lymph node transfer in lymphedema patients.
Plast Reconstr Surg Glob Open 2013;1.
[8] Abbas Khan MA, Mohan A, Hardwicke J, et al. Objective
improvement in upper limb lymphoedema following
ipsilateral latissimus dorsi pedicled flap breast
reconstructionea case series and review of literature. J Plast
Reconstr Aesthet Surg 2011;64:680.
[9] Blanchard M, Arrault M, Vignes S. Positive impact of delayed
breast reconstruction on breast-cancer treatment-related
arm lymphoedema. J Plast Reconstr Aesthet Surg 2012;65:
1060.
[10] Card A, Crosby MA, Liu J, Lindstrom WA, Lucci A,
Chang DW. Reduced incidence of breast cancer-related
lymphedema following mastectomy and breast
reconstruction versus mastectomy alone. Plast Reconstr
Surg 2012;130:1169.
[11] Saaristo A, Karkkainen MJ, Alitalo K. Insights into the
molecular pathogenesis and targeted treatment of
lymphedema. Ann N Y Acad Sci 2002;979:94.
[12] Baker A, Kim H, Semple JL, et al. Experimental assessment of
pro-lymphangiogenic growth factors in the treatment of
post-surgical lymphedema following lymphadenectomy.
Breast Cancer Res 2010;12:R70.
[13] Lahteenvuo M, Honkonen K, Tervala T, et al. Growth factor
therapy and autologous lymph node transfer in
lymphedema. Circulation 2011;123:613.
[14] Alitalo K. The lymphatic vasculature in disease. Nat Med
2011;17:1371.
j o u r n a l o f s u r g i c a l r e s e a r c h 1 9 9 ( 2 0 1 5 ) 7 1 8e7 2 5 725[15] Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K.
Proinflammatory cytokines regulate expression of the
lymphatic endothelial mitogen vascular endothelial growth
factor-C. J Biol Chem 1998;273:8413.
[16] Zampell JC, Avraham T, Yoder N, et al. Lymphatic function is
regulated by a coordinated expression of lymphangiogenic
and anti-lymphangiogenic cytokines. Am J Physiol Cell
Physiol 2012;302:C392.
[17] Avraham T, Clavin NW, Daluvoy SV, et al. Fibrosis is a key
inhibitor of lymphatic regeneration. Plast Reconstr Surg
2009;124:438.
[18] Avraham T, Daluvoy S, Zampell J, et al. Blockade of
transforming growth factor-beta1 accelerates lymphatic
regeneration during wound repair. Am J Pathol 2010;177:
3202.
[19] Tabibiazar R, Cheung L, Han J, et al. Inflammatory
manifestations of experimental lymphatic insufficiency.
PLoS Med 2006;3:e254.
[20] Brown SA, Mayberry AJ, Mathy JA, Phillips TM, Klitzman B,
Levin LS. The effect of muscle flap transposition to the
fracture site on TNFalpha levels during fracture healing.
Plast Reconstr Surg 2000;105:991.
[21] Busnardo FF, Coltro PS, Olivan MV, Busnardo AP, Ferreira MC.
The thoracodorsal artery perforator flap in the treatment of
axillary hidradenitis suppurativa: effect on preservation of
arm abduction. Plast Reconstr Surg 2011;128:949.
[22] Oliver G. Lymphatic vasculature development. Nat Rev
Immunol 2004;4:35.
[23] Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors
involved in angiogenesis versus lymphangiogenesis. Curr
Opin Cell Biol 2009;21:154.
[24] Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of
vascular endothelial growth factors. Cardiovasc Res 2005;
65:550.
[25] Szuba A, Pyszel A, Jedrzejuk D, Janczak D, Andrzejak R.
Presence of functional axillary lymph nodes and lymph
drainage within arms in women with and without breast
cancer-related lymphedema. Lymphology 2007;40:81.
[26] Yan A, Avraham T, Zampell JC, Aschen SZ, Mehrara BJ.
Mechanisms of lymphatic regeneration after tissue transfer.
PLoS One 2011;6:e17201.
[27] Tammela T, Alitalo K. Lymphangiogenesis: molecular
mechanisms and future promise. Cell 2010;140:460.
[28] Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF
receptor signallingdin control of vascular function. Nat Rev
Mol Cell Biol 2006;7:359.[29] Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial
growth factor D (VEGF-D) is a ligand for the tyrosine kinases
VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl
Acad Sci U S A 1998;95:548.
[30] Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in
development and human disease. Nature 2005;438:946.
[31] Tobler NE, Detmar M. Tumor and lymph node
lymphangiogenesisdimpact on cancer metastasis. J Leukoc
Biol 2006;80:691.
[32] Asadullah K, Sterry W, Volk HD. Interleukin-10
therapyereview of a new approach. Pharmacol Rev 2003;55:
241.
[33] Shi JH, Guan H, Shi S, et al. Protection against TGF-beta1-
induced fibrosis effects of IL-10 on dermal fibroblasts and its
potential therapeutics for the reduction of skin scarring.
Arch Dermatol Res 2013;305:341.
[34] Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med
1999;341:738.
[35] Peranteau WH, Zhang L, Muvarak N, et al. IL-10
overexpression decreases inflammatory mediators and
promotes regenerative healing in an adult model of scar
formation. J Invest Dermatol 2008;128:1852.
[36] Kieran I, Knock A, Bush J, et al. Interleukin-10 reduces scar
formation in both animal and human cutaneous wounds:
results of two preclinical and phase II randomized control
studies. Wound Repair Regen 2013;21:428.
[37] Li X, Mai J, Virtue A, et al. IL-35 is a novel responsive anti-
inflammatory cytokineda new system of categorizing anti-
inflammatory cytokines. PLoS One 2012;7:e33628.
[38] Clavin NW, Avraham T, Fernandez J, et al. TGF-beta1 is a
negative regulator of lymphatic regeneration during wound
repair. Am J Physiol Heart Circ Physiol 2008;295:H2113.
[39] Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-beta
family in wound healing, burns and scarring: a review. Int J
Burns Trauma 2012;2:18.
[40] Avraham T, Zampell JC, Yan A, et al. Th2 differentiation is
necessary for soft tissue fibrosis and lymphatic dysfunction
resulting from lymphedema. FASEB J 2013;27:1114.
[41] Cheng MH, Chen SC, Henry SL, Tan BK, Lin MC, Huang JJ.
Vascularized groin lymph node flap transfer for
postmastectomy upper limb lymphedema: flap anatomy,
recipientsites,andoutcomes.PlastReconstrSurg2013;131:1286.
[42] Dancey A, Nassimizadeh A, Nassimizadeh M, Warner RM,
Waters R. A chimeric vascularised groin lymph node flap and
DIEP flap for the management of lymphoedema secondary to
breast cancer. J Plast Reconstr Aesthet Surg 2013;66:735.
